DanCann Pharma receives approximately DKK 5.6 million from the exercise of series TO 2 together with a directed issue to the underwriters
COPENHAGEN, Denmark, 02 June 2023 - DanCann Pharma A/S (SS: DANCAN) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, today announces the outcome of the exercise of warrants of series TO2 (the “Warrants”) and a directed issue of shares. A total of 5,854,594 TO 2 warrants were exercised, corresponding to an exercise rate of approximately 27 percent. Prior to the exercise period, the Company also agreed on underwriting from external investors regarding the warrants that are not exercised by the warrant holders up to 71 percent of TO 2 warrants. Therefore, the